Subsequently, in vivo, experiments also demonstrated that inhibition of ABHD17C expression could sensitize the sensitivity of anti-PD1 therapy, significantly reduce tumor burden and promote the infiltration of effector T cells. Here, PDCD1 is linked to neoplasm.